Lambert Nicole's Form 4 filing
Myriad Genetics Inc (MYGN) · filed Sep 27, 2021
- Accession no.
- 0001770252-21-000011
- Filed
- Sep 27, 2021
- Trade date
- Sep 25-27, 2021
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 3 non-derivative transactions. Open-market sales total $334.7K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Lambert NicoleCIK 0001770252 | Officer (See Remarks) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 25, 2021 | Common Stock | FTax withholdingDisposed | −1,311 | $33.31 | −$43,669.41 | 191,610 | Direct | |
| Sep 26, 2021 | Common Stock | FTax withholdingDisposed | −3,426 | $33.31 | −$114,120.06 | 188,184 | Direct | |
| Sep 27, 2021 | Common Stock | SSaleDisposed | −10,112 | $33.10F3 | −$334,707.2 | 178,072 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.43 to $33.62, inclusive. The Reporting Person undertakes to provide to Myriad Genetics, Inc., any security holder of Myriad Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
Remarks
Ms. Lambert's title is Group President, Myriad Oncology, Myriad Women's Health and Myriad International.